At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase 2 Trial of Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating Pazopanib, Temsirolimus, and 2 other interventions for Kidney Cancer. Completed, enrolled 69 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to compare pazopanib to temsirolimus in the treatment of advanced clear-cell renal cell carcinoma. The safety of each drug will also be studied. Pazopanib is designed to block the growth of blood vessels that supply nutrients needed for tumor growth. This may prevent or slow the growth of cancer cells. Temsirolimus is designed to block the growth of cancer cells, which may cause cancer cells to die. This is an investigational study. Pazopanib and temsirolimus are both FDA approved and commercially available for the treatment of kidney cancer. It is investigational to compare the 2 drugs. Up to 90 patients will be enrolled in this study. All will be enrolled at MD Anderson.
Study Details
Timeline
Interventions
800 mg by mouth daily in 4 week study cycle.
25 mg by vein infused over 30-60 minutes every week in 4 week study cycle.
Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
25 to 50 mg by vein approximately 30 minutes before the start of each dose of temsirolimus.